First, A Quick Refresher on GLP-1s
GLP-1 receptor agonists, with brand names like Ozempic and Mounjaro, are a class of medications that have transformed the treatment of Type 2 diabetes and, more recently, obesity. They work by mimicking a natural gut hormone that signals fullness to the brain,
slows down how quickly your stomach empties, and helps the pancreas release insulin to manage blood sugar. For people with Type 2 diabetes, this dual action of improving blood sugar control while also promoting weight loss has been a game-changer. However, their high cost, side effects like nausea, and supply issues mean that many patients stop taking them.
A Major Study on Discontinuation
A large observational study published in early November 2026 in 'The Lancet Regional Health – Europe' provided a stark look at what happens when patients with Type 2 diabetes stop their GLP-1 medication. Researchers analyzed data from over 80,000 patients in Italy who had started on a GLP-1 drug but had no prior history of major cardiovascular events. They compared the outcomes of those who continued the treatment with the nearly two-thirds of patients who had stopped. The results highlight significant risks associated with discontinuation.
The Cardiovascular Risk Factor
The study's most alarming finding was related to heart health. Patients who stopped taking their GLP-1 medication had approximately double the risk of a non-fatal heart attack, non-fatal stroke, or death from any cause compared to those who remained on the treatment. The rate of these major events was about four per 100 people per year in the group that stopped, versus two per 100 in the group that continued. The risk of death from any cause was even more pronounced, with rates nearly five times higher in the discontinuation group.
Is It Cause and Effect?
It's crucial to understand that this was an observational study, which means it identifies a strong association but cannot prove direct causation. The researchers and outside experts caution that other factors could be at play. For instance, patients might stop the medication because their health is already deteriorating for other reasons, and this underlying poor health could be the true cause of the increased risk, not the act of stopping the drug itself. However, the findings are dramatic enough to reinforce the idea that the benefits of GLP-1s are tied to their continued use.
Weight Regain and Blood Sugar Rebound
Beyond the cardiovascular findings, stopping GLP-1s predictably leads to a reversal of their primary benefits. As the drug's effects wear off, appetite returns, digestion speeds back up, and the biological drivers of hunger reassert themselves. Studies have consistently shown that people who stop GLP-1s regain a significant portion of their lost weight, often two-thirds within a year. For patients with Type 2 diabetes, this is coupled with a rise in blood sugar levels and A1C, a phenomenon sometimes called a 'metabolic rebound', which can erase the hard-won gains in glycemic control.
Chronic Treatment for a Chronic Condition
The results of this and other discontinuation studies reinforce what most endocrinologists have been saying for years: Type 2 diabetes and obesity are chronic diseases that require long-term management. Much like medication for high blood pressure, GLP-1s are not a 'cure' but a tool that works as long as you take it. Discontinuing the therapy without a clear alternative plan often means the underlying condition—and its associated risks—will return. For patients with Type 2 diabetes, those risks go beyond weight and include serious cardiovascular events, underscoring the importance of a continuous treatment strategy.
















